Discovery and development of natural compounds into medicinal products

Drugs of the Future

Volumn 38, Issue 4, 2013, Pages 245-256

  Camp, David ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Drug discovery; Lead molecules; Natural compounds; New chemical entities

Indexed keywords

ACETYLSALICYLIC ACID; ARTEMETHER; ARTEMISININ; ARTESUNATE; ATORVASTATIN; CAMPTOTHECIN; CASPOFUNGIN; CEPHALOSPORIN C; DIGOXIN; DIHYDROARTEMISININ; DISCODERMOLIDE; EPOTHILONE D; ERIBULIN; FINGOLIMOD; GALANTAMINE; HALICHONDRIN B; HOMOHARRINGTONINE; IRINOTECAN; MORPHINE; NATURAL PRODUCT; PACLITAXEL; PENICILLIN G; PNEUMOCANDIN DERIVATIVE; QUININE; SALICYLIC ACID; TOPOTECAN;

DERIVATIZATION; DRUG INDUSTRY; HUMAN; REVIEW;

EID: 84930539358     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.04.1940442     Document Type: Review

References (77)

1. Newman, D.J., Cragg, CM., Snader, K.M. The influence of natural products upon drug discovery. Nat Prod Rep 2000,17(3): 215-34. (Pubitemid 30390787)
2. Sneader, W. Drug Discovery. A History. John Wiley & Sons: Chichester, West Sussex, U.K. 2005.
3. Ji, H.-R, Li, X.-J., Zhang, H.-Y. Natural products and drug discovery. EMBO Rep 2009,10(3): 194-200.
4. Farnsworth, N.R., Akerele, O., Bingel, A.S., Soejarto, D.D., Guo, Z. Medicinal plants in therapy. Bulletin WHO 1985, 63(6): 965-81. (Pubitemid 16055431)
5. Lam, K.S. New aspects of natural products in drug discovery. Trends Microbiol 2007,15(6): 279-89. (Pubitemid 46856162)
6. Newman, D.J., Cragg, CM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007, 70(3): 461-77. (Pubitemid 46595760)
7. Newman, D.J., Cragg, CM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012, 75(3): 311-35.
8. Newman, D.J. Natural products as leads to potential drugs: An old process or the new hope for drug discovery? J Med Chem 2008, 51(9): 2589-99. (Pubitemid 351620778)
9. Desai, M.C., Chackalamannil, S. Rediscovering the role of natural products in drug discovery. Curr Opin Drug Discov Devel 2008,11(4): 436-7. (Pubitemid 351950838)
10. Lipinski, C.A., Lombardo, R, Dominy, B., Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997, 23(1-3): 3-25. (Pubitemid 27046991)
11. Rouhi, A.M. Rediscovering natural products. Chem Eng News 2003, 81(41): 77-91.
12. Leeson, P.D., Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007, 6(11): 881-90. (Pubitemid 350042396)
13. Teague, S.J., Davis, A.M., Leeson, P.D., Oprea, T. The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 1999, 38(24): 3743-7.
14. Oprea, T.I., Davis, A.M., Teague, S.J., Leeson, P.D. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comp Sc 2001, 41(15): 1308-15.
15. Hann, M.M., Oprea, T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 2004, 8(3): 255-63. (Pubitemid 38759400)
16. Hesterkamp, T, Whittaker, M. Fragment-based activity space: Smaller is better. Curr Opin Chem Biol 2008,12(3): 260-8.
17. Rees, D.C, Congreve, M., Murray, C.W., Carr, R. Fragment-based lead discovery. Nat Rev Drug Discov 2004, 3(8): 660-72. (Pubitemid 39173507)
18. Leeson, P.D., Davis, A.M. Time-related differences in the physical property profiles of oral drugs. J Med Chem 2004, 47(25): 6338-48. (Pubitemid 39587257)
19. Camp, D, Davis, R.A., Campitelli, M., Ebdon, J., Quinn, R.J. Drug-like properties: Guiding principles for the design of natural product libraries. J Nat Prod 2012, 75(1): 72-85.
20. Salam, N.K., Huang, T.H.-W., Kota, B.P., Kim, M.S., Li, Y., Hibbs, D.E. Novel PPAR-gamma agonists identified from a natural product library: A virtual screening, induced-fit docking and biological assay study. Chem Biol Drug Des 2008, 71(1): 57-70.
21. Ehrman, T.M., Barlow, D.J., Hylands, P.J. In silico search for multi-target antiinflammatories in Chinese herbs and formulas. Bioorg Med Chem 2010,18(6): 2204-18.
22. Ma, D.-L., Chan, D.S.-H., Leung, C.-H. Molecular docking for virtual screening of natural product databases. Chem Sci 2011, 2(9): 1656-65.
23. McCullagh, M. Natural product pharmaceuticals: The third generation. Drug Discovery World 2008, 9(4): 69-73.
24. Davis, R.A., Carroll, A.R., Quinn, R.J. The synthesis of a combinatorial library using a tambjamine natural product template. Aust J Chem 2001, 54(6): 355-9. (Pubitemid 33694052)
25. Nicolaou, K.C., Pfefferkorn, J.A., Roecker, A.J., Cao, G.-Q., Barluenga, S., Mitchell, H.J. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of ben-zopyrans. J Am Chem Soc 2000,122(41): 9939-53.
26. Hall, D.C, Manku, S., Wang, R Solution- and solid-phase strategies for the design, synthesis and screening of libraries based on natural product templates: A comprehensive survey. J Combin Chem 2001, 3(2): 125-50.
27. Boldi, A.M. Libraries from natural product-like scaffolds. Curr Opin Chem Biol 2004, 8(3): 281-6. (Pubitemid 38759403)
28. Newman, D.J., Cragg, CM. Natural product scaffolds as leads to drugs. Future Med Chem 2009,1(8): 1415-27.
29. Hegde, V., Campitelli, M., Quinn, R.J., Camp, D. Synthesis of novel molecular probes inspired by harringtonolide. Org Biomol Chem 2011, 9(12): 4570-9.
30. Jenkins, I.D., Lacrampe, F, Ripper, J. et al. Synthesis of four novel natural product inspired scaffolds for drug discovery. J Org Chem 2009, 74(3): 1304-13.
31. Thomas, G.L., Johannes, C.W. Natural product-like synthetic libraries. Curr Opin Chem Biol 2011,15(4): 516-22.
32. Shoichet, B.K. Drug discovery: Nature's pieces. Nat Chem 2013, 5(1): 9-10.
33. Over, B., Wetzel, S., Grütter, C, Nakai, Y., Renner, S., Rauh, D., Waldmann, H. Natural-product-derived fragments for fragment-based lig-and discovery. Nat Chem 2013, 5(1): 21-8.
34. Shu, Y.-Z. Recent natural products based drug development: A pharmaceutical industry perspective. J Nat Prod 1998, 61(8): 1053-71. (Pubitemid 28417273)
35. Kinghorn, A.D., Pan, L, Fletcher, J.N., Chai, H. The relevance of higher plants in lead compound discovery programs. J Nat Prod 2011, 74(6): 1539-55.
36. Cordell, G.A., Colvard, M.D. Natural products and traditional medicine: Turning on a paradigm. J Nat Prod 2012, 75(3): 514-25.
37. Schmitz, R.F. Wilhelm Serturner and the discovery of morphine. Pharm Hist 1985, 27(2): 61-74.
38. Rishton, CM. Natural products as a robust source of new drugs and drug leads: Past successes and present day issues. Am J Cardiol 2008,101(10A): 43D-9D.
39. Aronson, J.K. An Account of the Foxglove and its Medical Uses 1785-1985. Oxford University Press: Oxford 1985.
40. Heinrich, M., Teoh, H.-L. Calanthamine from snowdrop - The development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol 2004, 92(2-3): 147-62. (Pubitemid 38610095)
41. Bindseil, K.U., Jakupovic, J., Wolf, D., Lavayre, J., Leboul, J., van der Pyl, D. Pure compound libraries; a new perspective for natural product based drug discovery. Drug Discov Today 2001, 6(16): 840-7. (Pubitemid 32734512)
42. Abel, U., Koch, C, Speitling, M., Hansske, F.G. Modern methods to produce natural-product libraries. Curr Opin Chem Biol 2002, 6(4): 453-8. (Pubitemid 34804767)
43. Quinn, R.J., Carroll, A.R., Pham, N.B. et al. Developing a drug-like natural product library. J Nat Prod 2008, 71(3): 464-8. (Pubitemid 351549376)
44. Hert, J., Irwin, J.J., Laggner, C, Keiser, M.J., Shoichet, B.K. Quantifying biogenic bias in screening libraries. Nat Chem Biol 2009, 5(7): 479-83.
45. Camp, D., Davis, R.A., Evans-lllidge, E.A., Quinn, R.J. Guiding principles for natural product drug discovery. Future Med Chem 2012, 4(9): 1067-84.
46. Pereira, D.A., Williams, J.A. Origin and evolution of high throughput screening. Br J Pharmacol 2007,152(1): 53-61. (Pubitemid 47339909)
47. Kingston, D.G.I. Modem natural products drug discovery and its relevance to biodiversity conservation. J Nat Prod 2011, 74(3): 496-511.
48. Wagenaar, M.M. Pre-fractionated microbial samples - The second generation natural products library at Wyeth. Molecules 2008,13(6): 1406-26.
49. Appleton, D.R., Buss, A.D., Butler, M.S. A simple method for high-throughput extract prefractionation for biological screening. Chimia 2007, 61(6): 327-31.
50. Baell, J.B. Observations on screening-based research and some concerning trends in the literature. Future Med Chem 2010, 2(10): 1529-46.
51. Baell, J.B., Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010, 53(7): 2719-40.
52. Eldridge, G.R., Veroort, H.C., Lee, CM. et al. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal Chem 2002, 74(16): 3963-71. (Pubitemid 34912891)
53. Tu, Y, Jeffries, C, Ruan, H. et al. Automated high-throughput system to fractionate plant natural products for drug discovery. J Nat Prod 2010, 73(4): 751-4.
54. Shoichet, B.K. Screening in a spirit haunted world. Drug Discov Today 2006,11(13-14): 607-15.
55. Thorne, N., Auld, D.S., Inglese, J. Apparent activity in high-throughput screening: Origins of compound-dependent assay interference. Curr Opin Chem Biol 2010,14(3): 315-24.
56. Bugni, T.S., Richards, B., Bhoite, L, Cimbora, D., Harper, M.K., Ireland, CM. Marine natural product libraries for high-throughput screening and rapid drug discovery. J Nat Prod 2008, 71(6): 1095-8. (Pubitemid 352008917)
57. Ganesan, A. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol 2008,12(3): 306-17.
58. Lombardo, F, Shalaeva, M.Y., Tupper, K.A., Gao, F, Abraham, M.H. ElogPoct: A tool for lipophilicity determination in drug discovery. J Med Chem 2000, 43(15): 2922-8. (Pubitemid 30599650)
59. Bollag, D.M., McQueney, P.A., Zhu, J. et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995, 55(11): 2325-33.
60. Walker, S.R., Carter, E.J., Huff, B.C., Morris, J.C. Variolins and related alkaloids. Chem Rev 2009,109(7): 3080-98.
61. Kingston, D.G.I. Recent advances in the chemistry of taxol. J Nat Prod 2000, 63(5): 726-34. (Pubitemid 30395547)
62. Koehn, F.E., Carter, G.T. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005, 4(3): 206-20. (Pubitemid 40372555)
63. Cragg, CM., Grothaus, PC, Newman, D.J. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009,109(7): 3012-43.
64. Li, J.W.-H., Vederas, J.C. Drug discovery and natural products: End of an era or an endless frontier? Science 2009, 325(5937): 161-5.
65. Ikeda, Y, Idemoto, H., Hirayama, F, Yamamoto, K., Iwao, K., Asao, T, Munakata, T. Safracins, new antitumor antibiotics. I. Producing organism, fermentation and isolation. J Antibiot 1983, 36(10): 1279-83. (Pubitemid 14232192)
66. Cuevas, C, Perez, M., Martin, M.J. et al. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett 2000, 2(16): 2545-8.
67. Kennedy, J. Mutasynthesis, chemobiosynthesis, and back to semi-synthesis: combining synthetic chemistry and biosynthetic engineering for diversifying natural products. Nat Prod Rep 2008, 25(1): 25-34. (Pubitemid 351207544)
68. Stein, G.E., Craig, W.A. Tigecycline: A critical analysis. Clin Infect Dis 2006, 43(4): 518-24. (Pubitemid 44157163)
69. Mickel, S.J., Sedelmeier, G.H., Niederer, D. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 1: Synthetic strategy and preparation of a common precursor. Org Proc Res Dev 2004, 8(1): 92-100. (Pubitemid 38175718)
70. Mickel, S.J., Sedelmeier, G.H., Niederer, D. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 2: Synthesis of fragments Cl-6 and C9-14. Org Proc Res Dev 2004, 8(1): 101-6. (Pubitemid 38175719)
71. Mickel, S.J., Sedelmeier, G.H., Niederer, D. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 3: Synthesis of fragment 05-2I. Org Proc Res Dev 2004, 8(1): 107-12. (Pubitemid 38175720)
72. Mickel, S.J., Sedelmeier, G.H., Niederer, D. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 4: Preparation of fragment C7-24. Org Proc Res Dev 2004, 8(1): 113-21. (Pubitemid 38175721)
73. Mickel, S.J., Niederer, D., Daeffler, R. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 5: Linkage of fragments Cl-6 and C7-24 and finale. Org Proc Res Dev 2004, 8(1): 122-30. (Pubitemid 38175722)
74. Freemantle, M. Scaled-up synthesis of discodermolide. Chem Eng News 2004, 82(9): 33-5.
75. Strader, C.R., Pearce, C.J., Oberlies, N.H. Fingolimod (FTY720): A recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod 2011, 74(4): 900-7.
76. Haynes, R.K., Chan, H.-W., Cheung, M.-K. etal. C-10 Ester and ether derivatives of dihydroartemisinin - 10-a artesunate, preparation of authentic 10-b artesunate, and of other ester and ether derivatives bearing potential aromatic intercalating groups at C-10. Eur J Org Chem 2002(1): 113-35.
77. Lee, M.L., Schneider, G. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: Application in the design of nat-ural product-based combinatorial libraries. J Combin Chem 2001, 3(3): 284-9. (Pubitemid 33616450)